Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug2948 | SARS-CoV2 serum antibody testing Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
D018352 | Coronavirus Infections NIH | 0.03 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
As a direct consequence of the COVID-19 pandemic, it is assumed that the number of patients with COVID-19-related disabilities will increase significantly. Patients with mild, severe, and critical forms of the disease show long-term sequelae in different systems (respiratory, muscular, psychological, cognitive etc.). Persistent dyspnea is a frequently described symptom after the acute phase of the disease. Coupled with reduced oxygen saturation, an increased risk of developing lung fibrosis has been observed. Specialized rehabilitation medicine (e.g. pulmonary rehabilitation) might counteract these long-term consequences and therefore seems to be a promising approach to treat long-term COVID-19 consequences. Further, there is scarce evidence about COVID-19 specific rehabilitation contents. It was suggested to use treatment regimes in analogy to patients with idiopathic pulmonary fibrosis. There is evidence that pulmonary rehabilitation improves physical performance, quality of life and reduces anxiety and depression symptoms in patients with idiopathic pulmonary fibrosis and other chronic respiratory diseases. Since impairments related to idiopathic pulmonary fibrosis also play an important role in COVID-19, the aim of this study is to evaluate the short and medium-term effects of a standardized 3-week pulmonary rehabilitation program. The results will be analyzed within the two cohorts (mild/moderate and severe/critical COVID 19) as well as between the two cohorts for the primary outcome. Furthermore, the effects of pulmonary rehabilitation will be compared with a retrospective cohort of idiopathic pulmonary fibrosis.
Description: measure in meter
Measure: Change in 6-minute walk distance Time: Day 1 and day 21 of pulmonary rehabilitationDescription: measure provided in seconds
Measure: change in endurance shuttle walk distance Time: Day 1 and day 21 of pulmonary rehabilitationDescription: measure provided in % predicted
Measure: Change in Diffusion capacity of the lungs for Carbon monoxide Time: Day 1 and day 21 of pulmonary rehabilitationDescription: measure provided in % predicted
Measure: Change in Forced Vital Capacity Time: Day 1 and day 21 of pulmonary rehabilitationDescription: measure provided in % predicted
Measure: Change in total lung capacity Time: Day 1 and day 21 of pulmonary rehabilitationDescription: score ranges from 0 to 30 with lower score indicating higher cognitive impairment
Measure: change in Montreal cognitive assessment test Time: Day 1 and day 21 of pulmonary rehabilitationDescription: score ranges from 0 to 100 with higher scores indicating better Quality of life
Measure: change in short-form 36 question health survey Time: Day 1 and day 21 of pulmonary rehabilitation and day 90 following pulmonary rehabilitationDescription: A questionnaire designed to measure self-reported physical, mental and social health and wellbeing. Higher scores represent worse symptomatology in relation to the mean value of 50 points with a standard deviation of 10 points.
Measure: change in Patient-Reported Outcomes Measurement Information System - 29 (PROMIS-29) Time: Day 1 and day 21 of pulmonary rehabilitation and day 90 following pulmonary rehabilitationDescription: score ranges from 0 to 21 with higher scores indicating more severe anxiety
Measure: Change in the scale of general anxiety disorder - 7 questionnaire (GAD-7) Time: Day 1 and day 21 of pulmonary rehabilitation and day 90 following pulmonary rehabilitationDescription: score ranges from 0 to 27 with higher scores indicating more severe depression
Measure: Change in the scale of the patient health questionnaire - Depression (PHQ-D) Time: Day 1 and day 21 of pulmonary rehabilitation and day 90 following pulmonary rehabilitationDescription: patients will be asked if they still perceive COVID-19 related dyspnea: answer possibilities yes or no
Measure: Change in prevalence of COVID-19 related dyspnea Time: Day 1 and day 21 of pulmonary rehabilitation and day 90 following pulmonary rehabilitationDescription: patients will be asked if they still perceive COVID-19 related cough: answer possibilities yes or no
Measure: Change in prevalence of COVID-19 related cough Time: Day 1 and day 21 of pulmonary rehabilitation and day 90 following pulmonary rehabilitationDescription: patients will be asked if they still perceive COVID-19 related cognitive impairment: answer possibilities yes or no
Measure: Change in prevalence of COVID-19 related cognitive impairment Time: Day 1 and day 21 of pulmonary rehabilitation and day 90 following pulmonary rehabilitationDescription: patients will be asked if they still perceive COVID-19 related loss of appetite: answer possibilities yes or no
Measure: Change in prevalence of COVID-19 related loss of appetite Time: Day 1 and day 21 of pulmonary rehabilitation and day 90 following pulmonary rehabilitationDescription: scale from 1 (worst) to 10 (best)
Measure: Change in general perceived well-being Time: Day 1 and day 21 of pulmonary rehabilitation and day 90 following pulmonary rehabilitationDescription: in mg/l
Measure: change in D-Dimer level Time: Day 1 and day 21 of pulmonary rehabilitationDescription: in mg/l
Measure: change in c-reactive protein level Time: Day 1 and day 21 of pulmonary rehabilitationDescription: in g/l
Measure: change in leukocytes level Time: Day 1 and day 21 of pulmonary rehabilitationDescription: in g/dl
Measure: change in hemoglobin level Time: Day 1 and day 21 of pulmonary rehabilitationDescription: in pg/ml
Measure: change in troponin level Time: Day 1 and day 21 of pulmonary rehabilitationDescription: in pg/ml
Measure: change in pro-brain natriuretic peptide level Time: Day 1 and day 21 of pulmonary rehabilitationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports